Alphatec/$ATEC
1D1W1MYTD1Y5YMAX
Capital at risk
About Alphatec
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
- Ticker
- $ATEC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 913
- Headquarters
- Carlsbad, United States
- Website
- www.atecspine.com
Alphatec Metrics
BasicAdvanced
$1.7B
-
-$0.72
0.85
-
Price and volume
Market cap
$1.7B
Beta
0.85
52-week high
$23.29
52-week low
$6.82
Average daily volume
2.3M
Financial strength
Current ratio
1.887
Quick ratio
0.993
Long term debt to equity
46.16
Total debt to equity
52.369
Interest coverage (TTM)
-0.80%
Profitability
EBITDA (TTM)
38.364
Gross margin (TTM)
70.84%
Net profit margin (TTM)
-13.50%
Operating margin (TTM)
-4.76%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$890,000
Management effectiveness
Return on assets (TTM)
-3.07%
Return on equity (TTM)
-373.44%
Valuation
Price to revenue (TTM)
2.046
Price to book
-137.39
Price to tangible book (TTM)
-9.5
Price to free cash flow (TTM)
-290.584
Free cash flow yield (TTM)
-0.34%
Free cash flow per share (TTM)
-0.037
Growth
Revenue change (TTM)
19.47%
Earnings per share change (TTM)
-36.92%
3-year revenue growth (CAGR)
24.55%
10-year revenue growth (CAGR)
19.88%
3-year earnings per share growth (CAGR)
-22.12%
10-year earnings per share growth (CAGR)
-28.89%
What the Analysts think about Alphatec
Analyst ratings (Buy, Hold, Sell) for Alphatec stock.
Analyst projections of the future price of Alphatec stock.
Bulls say / Bears say
ATEC’s core surgical business is showing strong momentum: Q2 2026 total revenue rose 15% year over year to $214 million, surgical revenue increased 17%, and case volume grew 20%. (Alphatec)
Operating leverage is improving: Q2 adjusted EBITDA rose to $36 million, or 16.8% of revenue, up 420 basis points year over year; the company also reported positive free cash flow and a 24% increase in net new surgeon users. (Alphatec)
Management reaffirmed its 2026 outlook for approximately $882 million of revenue, $134 million of adjusted EBITDA, and at least $20 million of free cash flow; the May refinancing is expected to reduce annual interest expense by more than $6 million and extend maturities to 2031. (Alphatec)
ATEC’s growth has not yet translated into GAAP profitability: it reported a $25.8 million net loss in Q2 2026 and a $59.7 million net loss for the first half, while weighted-average shares increased year over year, creating dilution risk. (SEC)
The balance sheet remains highly leveraged after the May refinancing, with $175 million of term debt, $40 million drawn on the revolver, and $405 million of convertible notes; the JPM facilities carried an effective interest rate of 6.7% at June 30, 2026 and impose leverage and fixed-charge covenants. (SEC)
Liquidity could remain pressured by expansion spending: cash fell to $118.7 million from $160.8 million at year-end, inventory rose to $194.9 million, and first-half investing cash use of $42.6 million exceeded operating cash generation of $21.8 million; the filing also recorded an $8.1 million inventory write-down. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
Alphatec Financial Performance
Revenues and expenses
Alphatec Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alphatec News
AllArticlesVideos
Funds containing Alphatec
AllEURUSDGBP
Fund name | Fund size | $ATEC weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.